Dynavax begins clinical trial for new shingles vaccine candidate, Z-1018
Dynavax Technologies Corporation, a renowned player in the biopharmaceutical sector, has made headlines with the initiation of a Phase 1/2 clinical trial for its innovative shingles vaccine candidate, Z-1018. This trial marks a significant step in the development of a vaccine aimed at preventing shingles, a painful condition caused by the reactivation of the varicella-zoster virus.
The first participant has been dosed in this trailblazing study, which seeks to evaluate the safety, tolerability, and immunogenicity of Z-1018. Taking place in Australia, the trial is set to enroll approximately 440 healthy adults between the ages of 50 and 69. This research is pivotal as it compares the new vaccine candidate against Shingrix, the current market leader.
Rob Janssen, M.D., Chief Medical Officer at Dynavax, expressed optimism about the potential of Z-1018, highlighting its use of the CpG 1018 adjuvant known for its safety and the ability to induce strong CD4+ T-cell responses. These responses are crucial for preventing the virus’s reactivation.
“Z-1018 represents a significant advancement in our vaccine portfolio, offering potentially better tolerability compared to existing shingles vaccines. Our focus is not only on preventing shingles but also on improving the quality of life for those vaccinated,” said Janssen.
The trial’s design is thorough, with a focus on selecting the optimal dose levels and scheduling for further development. It also aims to validate a Patient Reported Outcome measurement tool, which could help differentiate Z-1018 based on tolerability and support potential label claims.
The importance of this trial extends beyond its immediate impact. Shingles can lead to severe complications, including chronic pain. Despite available treatments, there remains a significant unmet medical need for more effective and tolerable vaccines.
Dynavax anticipates releasing top-line immunogenicity and safety data in the second half of 2025. This data will include a crucial comparison of CD4+ T-cell responses, a month after the administration of the second vaccine dose.
The launch of this clinical trial by Dynavax Technologies is a promising development in the field of vaccine research. It not only addresses the need for more effective shingles prevention strategies but also highlights the ongoing innovation in vaccine technology, potentially setting a new standard for treatment options.